medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2006, Number 1

<< Back Next >>

Ann Hepatol 2006; 5 (1)

Occult hepatitis B in mexican patients with HIV, an analysis using nested polymerase chain reaction

Torres-Baranda R, Bastidas-Ramírez BE, Maldonado-González M, Sánchez-Orozco LV, Vázquez-Vals E, Rodríguez-Noriega E, Panduro A

Language: English
References: 44
Page: 34-40
PDF size: 67.74 Kb.


Text Extraction

Hepatitis B virus infection (HBV) with undetectable levels of HBsAg, has been named occult HBV infection and observed in immunosuppressed patients. The aim of this study was to determine the frequency of occult HBV infection in patients with HIV from the West of México, using a combination of serological markers and nPCR. Thirty eight HIV/AIDS patients, 32 men (84.2%) and 6 (5.8%) women, without liver damage related symptoms were studied. HBV coinfection was observed in 10 (26.3%) patients; while only 3 (7.9%) of them were positive to HBsAg. Thus, 7 (18.4%) occult HBV infected patients could be assessed in this population. One (10%) patient with occult HBV infection was positive to anti-HBs, in spite of the reinfection protection attributed to this serological marker. Anti-HBc was detected only in 2 (20%) patients with occult HBV infection. No significant association could be established between occult HBV infection and CD+4 cell count, biochemical, clinical parameters, AIDS stage, or any other risk factor. This study suggest that determination of HBV DNA utilizing highly sensitive techniques, as nPCR, should be performed to detect occult HBV infection, even in the absence of anti-HBc in HIV/AIDS patients, in order to have a reliable diagnosis, prevent HBV dissemination and acute exacerbation of chronic hepatitis B or even fulminant hepatitis. To our knowledge this is the first study of occult HBV infection in Mexican patients with HIV. However, further studies are necessary in order to determine HBV genotypes and its relationship with evolution and clinical manifestation of the disease.


REFERENCES

  1. Lau JYN, Wright TL. Molecular virology and pathogenesis of hepatitis B. Lancet 1993; 342: 1335-1340.

  2. Ganem D, Prince AM. Hepatitis B virus infection, natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129.

  3. Mahoney FJ. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999; 12: 351-366.

  4. Coursaget P, LeCann P, Leboulleux D, Diop MT, Bao O, Coll AM. Detection of hepatitis B virus DNA by polymerase chain reaction in HBsAg negative Senegalense patients suffering from cirrhosis or primary liver cancer. FEMS Microbiol Lett 1991; 67: 35-39.

  5. Rustgi V, Hoofnagle JH, Guerin JL, Gelmann EP, Reichert CM, Cooper JN, Macher AM. Hepatitis B infection in the acquired immunodeficiency syndrome. Ann Intern Med 1984; 101(6): 795-797.

  6. Chamorro AJ, Casado JL, Bellido D, Moreno S. Reactivation of hepatitis B in an HIV-infected patient with antibodies against hepatitis B core antigen as the only serological marker. Eur J Clin Microbiol Infect Dis 2005; 24: 492-494.

  7. Koff RS. Hepatitis B and Hepatitis D, In S. L. Gorbach, J. G. Bartlett, N. R. Blacklow, eds. Infectious Dissease, 3rd ed. Philadelphia, PA. Lippncott Williams and Wilkins, Inc., 2004; 765-784.

  8. Hoofnagle H, Di Bisceglie AM. Serologic diagnosis of acute and chronic viral hepatitis. Semin Liver Dis 1991; 11: 73-83.

  9. De Maria N, Colantoni A, Friedlander L, Leandro G, Idilman R, Harig J, Van Thiel DH. The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol 2000; 95(12): 3529-36.

  10. Fukuda R, Ishimura N, Niigaki M, Hamamoto S, Satoh S, Tanaka S, Kushiyama Y, et al. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol 1999; 58(3): 201-7.

  11. Torbenson M, Thomas DL. Occult hepatitis B Lancet Infect Dis 2002; 2: 479-486.

  12. Conjeevaram HS, Lok AS. Occult hepatitis B virus infection: a hidden menace. Hepatology 2001; 34: 204-205.

  13. Carman WF, Van Deursen FJ, Mimms LT, Hardie D, Coppola R, Decker R, Sanders R. The prevalence of surface antigen variants of Hepatitis B virus in Papua New Guinea, South Africa and Sardinia. Hepatology 1997; 26: 1658-1666.

  14. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely ‘occult’? Hepatology 2001; 34: 194-203.

  15. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120: 1009-1022.

  16. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-188.

  17. Vandercam B, Cornu C, Gala JL, Geubel A, Cahill M, Lamy ME. Reactivation of hepatitis B virus in a previously immune patient with human immunodeficiency virus infection. Eur J Clin Microbiol Infect Dis 1990; 9(9): 701-702.

  18. 18ª asamblea Médica Mundial, Helsinki, Finlandia, en Junio de 1964 y revisados en la 52ª Asamblea general de Edimburgo, Escocia, octubre de 2000.

  19. Yokosuka O, Tagawa M, Omata M. PCR detection of Hepatitis B Virus. In: Persing DH, Smith TF, Tenover FC, White TJ, eds. Diagnostic molecular microbiology principles and applications, 1st ed. Washington, DC: American Society for Microbiology. 1993; 32-325.

  20. Sánchez LV, Maldonado M, Bastidas-Ramírez BE, Norder H, Panduro A. Genotypes and S-Gene variability of Mexican Hepatitis B virus Strains. J Med Virol 2002; 68: 24-32.

  21. Thiers V, Nakajima E, Kremsdorf D, Mack D, Schellekens H, Driss F, Goudeau A, et al. Transmission of hepatitis B from hepatitis-B-seronegative subjects. Lancet 1988; 2: 1273-1276.

  22. Liang T, Hasegawa K, Rimon N, Wands J, Ben-Porath E. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. New Engl J Med 1991; 4: 1705-1709.

  23. Salmon-Ceron D, Lewden C, Morlar P, Bévilacqua S, Jougla E, Bonnet F, Héripret L, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatology 2005; 42: 799-805.

  24. Paterlini P, Gerken G, Nakajima E, Terre S, D’Errico A, Grigioni W, Nalpas B, et al. Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen. New Engl J Med 1990; 323: 80-85.

  25. Cabrerizo M, Bartolome J, De Sequera P, Caramelo C, Carreno V. Hepatitis B virus DNA in serum and blood cells of hepatitis B surface antigen-negative hemodialysis patients and staff. J Am Soc Nephrol 1977; 8: 1443-1447.

  26. Nuñez M, Rios P, Perez-Olmeda M, Soriano V. Lack of ‘occult’ hepatitis B virus infection in HIV-infected patients. AIDS 2002; 18(15): 2099-2101.

  27. Baginski I, Chemin I, Hantz O, Pichoud C, Jullien AM, Chevre JC, Li JS, et al. Transmission of serologically silent hepatitis-b virus along with hepatitis-c virus in two cases of posttransfusion hepatitis. Transfusion 1992; 32: 215-220.

  28. Hui Ch, Sun J, Au W, Lie AKW, Yueng Y, Zhang H, Lee NP, et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatology 2005; 42: 813-819.

  29. Shire NJ, Rouster SD, Rajicic NBS, Sherman KE. Occult Hepatitis B in HIV-Infected Patients. J Acquir Immune Defc Syndr 2004; 36(3): 860-875.

  30. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991; 163: 1138-1140.

  31. Gilson RJ, Hawkins AE, Beecham MR, Ross E, Waite J, Briggs M, McNally T, et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS 1997; 11(5): 597-606.

  32. Homann C, Krogsgaard K, Petersen C, Andersson P, Nielsen JQ. High incidence of hepatitis B infection and evolution of chronic hepatitis B infection in patients with advanced HIV infection. J Acquir Immune Defy Syndr 1991; 4: 416-420.

  33. Kingsley LA, Rinaldo CR Jr, Lyter DW, Valdiserri RO, Belle SH, Ho M. Sexual transmission efficiency of hepatitis B virus and human immunodeficiency virus among homosexual men. JAMA 1990; 264(2): 230-4.

  34. Laure F, Zagury D, Saimot AG, Gallo RO, Hahn BH, Brechor C. Hepatitis B virus DNA sequences in lymphoid cells from patients with AIDS and AIDS-related complex. Science 1985; 229: 561-63.

  35. Thimme R, Spangenberg HC, Blum HE. Hepatitis B or hepatitis C and human immunodeficiency virus infection. J Hepatology 2005; 42: S37-S44.

  36. Hawkins AE, Gilson RJ, Gilbert N, Wreghitt TG, Gray JJ, Ahlersde Boer I, Tedder RS, et al. Hepatitis B virus surface mutations associated with infection after liver transplantation. J Hepatol 1996; 24(1): 8-14.

  37. Weinberger KM, Bauer T, Bohm S, Jilg W. High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum. J Gen Virol 2000; 81: 1165-1174.

  38. Lebovics E, Dworkinn B, Heier S, Rosenthal W. The hepatobilliary manifestations of human immunodeficiency virus infection. Am J Gastroenterol 1988; 83: 1-7.

  39. Thio CL. Hepatitis B in the human immunodeficiency virusinfected patient: Epidemiology, Natural History, and treatment. Seminars Liv Dis 2003; 23(2): 125-136.

  40. Hofer M, Joller-Jemelka HI, Grob PJ, Luthy R, Opravil M. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis 1998; 17: 6-13.

  41. Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palù G, et al. Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatology 2005; 42: 615-624.

  42. Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepatitis 2002; 9: 243-257.

  43. Raimondo G, Cacciamo C, Saitta C. Hepatitis B virus and hepatitis C virus co-infection additive players in chronic liver disease? Annals of Hepatology 2005; 4(2): 100-106.

  44. García-Montalvo BM, Farfán-Ale JA, Acosta-Viana KY, Puerto-Manzano FI. Hepatitis B virus DNA in blood donors with anti-HBc as a possible indicator of active hepatitis B virus infection in Yucatan, México. Transfus Med 2005; 15(5): 371-378.




2020     |     www.medigraphic.com